Digitala Vetenskapliga Arkivet

Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
β3-adrenergic antagonism alleviates weight loss associated with cancer cachexia
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Fysiologisk kemi.
2017 (engelsk)Independent thesis Basic level (professional degree), 20 poäng / 30 hpOppgave
Abstract [en]

Cancer induced cachexia (CIC) is a devastating wasting disorder affecting people with tumor diseases and is deemed responsible for approximately 20% of all cancer-related deaths. This syndrome is associated with atrophy of adipose tissue and skeletal muscle. No established treatment is available for CIC and the underlying mechanisms are unveiled. However, one proposed culprit is brown adipose tissue (BAT) and browning of white adipose tissue (WAT), which produces heat via activation uncoupling protein 1 (UCP1). The result is increased energy wasting. Β3-adrenergic receptor (ADRB3) signaling activates BAT and we hypothesized that treatment with a specific ADRB3 antagonist would mitigate energy wasting in CIC. Balb/ca nude mice implanted with the LuCAP32 human xenograft tumor was used as a model system for CIC. The mice were treated with the selective ADRB3-blocker SR59230A and the unselective ADRB1 and 2-blocker propranolol for 4 weeks. A vehicle (VEH) and non-tumor bearing (NTB) group was also used. Significant effects were seen on total body weight loss with SR-treatment compared to VEH. Similar effects were seen on the wasting of local WAT depots. When measuring body composition, we found moderate evidence that SR spares the wasting of lean mass. We were also able to show decreased gene expression of BAT-markers, as well as markers for lipolysis, in the subcutaneous WAT. This supports our main hypothesis. In conclusion, we can show that treatment with a selective ADRB3 antagonist alleviates the symptoms of CIC through decreased lipolysis and decreased browning of WAT. These findings add to the mechanistic understanding of the pathophysiology of CIC and could be a potential treatment strategy for this syndrome.

sted, utgiver, år, opplag, sider
2017. , s. 13
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-143518OAI: oai:DiVA.org:umu-143518DiVA, id: diva2:1170427
Utdanningsprogram
Medical Programme
Veileder
Examiner
Tilgjengelig fra: 2018-06-25 Laget: 2018-01-03 Sist oppdatert: 2018-06-25bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric

urn-nbn
Totalt: 747 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf